EUVIMEDEUVIMED entdecken
Crossref

Stem-like CD8 T cells in stage I lung adenocarcinoma as a prognostic biomarker: A preliminary study

Jing Sang, Peng Liu, Meixiang Wang, Fengkuo Xu, Ji Ma, Zhigang Wei, Xin Ye

Journal of Cancer Research and Therapeutics · 2024

DOI: 10.4103/jcrt.jcrt_2453_23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Therapeutics, 2024. Verfasst von Jing Sang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, CD8-Positive T-Lymphocytes, Lung Neoplasms, Neoplasm Staging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study aimed to investigate the presence of stem-like CD8 T (CD8 T SL ) cells in lung adenocarcinoma (LUAD) and explore their relationships with the clinical outcomes.

Methods

Multiplex immunofluorescence (mIF) was performed to identify CD8 T SL and antigen-presenting cells (APC) in 76 LUAD patients. Differences in the number of CD8 T SL cells based on tumor stage and the spatial relationships between CD8 T SL cells and APC niches were determined. The optimal cutoff value of CD8 T SL cells for predicting survival in patients with stage I LUAD was calculated.

Results

CD8 T SL cells were present in all tumors, and their numbers were significantly higher in stage I patients than in stage III patients ( P = 0.010); CD8 T SL cells located in the APC niches accounted for 69.7% (53/76) of the hotspot fields. The optimal cutoff value for the number of CD8 T SL cells required to predict the overall survival (OS) in patients with stage I LUAD was 2.5 per 10000 μm 2 . The median OS and progression-free survival (PFS) in the high-level group (>2.5) were significantly ( P < 0.001) longer than those in the low-level group (≤2.5). The number of CD8 T SL cells was an independent prognostic factor for stage I LUAD. Patients with more CD8 T SL cells had a lower risk of death and disease progression than those with less CD8 T SL cells.

Conclusion

CD8 T SL cells were observed in patients with stages I–III LUAD and might serve as prognostic biomarkers for stage I LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungCD8-Positive T-LymphocytesLung NeoplasmsNeoplasm StagingBiomarkers, TumorHumansPrognosisFemaleMaleMiddle AgedAgedAdult

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Tr…
  • Department of Pathology, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China.

Zitieren

APA

Sang, J., Liu, P., Wang, M., Xu, F., Ma, J., Wei, Z., & Ye, X. (2024). Stem-like CD8 T cells in stage I lung adenocarcinoma as a prognostic biomarker: A preliminary study. Journal of Cancer Research and Therapeutics. https://doi.org/10.4103/jcrt.jcrt_2453_23

Vancouver

Sang J, Liu P, Wang M, Xu F, Ma J, Wei Z, et al. Stem-like CD8 T cells in stage I lung adenocarcinoma as a prognostic biomarker: A preliminary study. Journal of Cancer Research and Therapeutics. 2024. doi:10.4103/jcrt.jcrt_2453_23

BibTeX
@article{Sang2024,
  author = {Sang, Jing and Liu, Peng and Wang, Meixiang and Xu, Fengkuo and Ma, Ji and Wei, Zhigang and Ye, Xin},
  title = {Stem-like CD8 T cells in stage I lung adenocarcinoma as a prognostic biomarker: A preliminary study},
  journal = {Journal of Cancer Research and Therapeutics},
  year = {2024},
  doi = {10.4103/jcrt.jcrt_2453_23}
}
Kostenlos starten →